Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Natpar 75 micrograms/dose powder and solvent for solution for injection {equilateral_black_triangle}

Active Ingredient:
parathyroid hormone
Company:  
Takeda UK Ltd See contact details
ATC code: 
H05AA03
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Letters to HCPs HCP Med Info
{arrow_left}
{arrow_right}

Important information for Healthcare Professionals

{pdf_link}

NATPAR (parathyroid hormone)▼ DHPC: Update stock availability and Marketing Authorisation Withdrawal

{healthcare_pro_orange} For Healthcare Professionals

Communications on UK supply updates, please find attached an important communication on the ongoing supply and marketing of Natpar (parathyroid hormone)▼ in the UK. Please read this communication carefully as it details important information about the discontinuation of Natpar supply to the UK on 30th April 2026 and the subsequent withdrawal of Natpar’s marketing authorisation in the UK on 1st July 2026.

{pdf_link}

Natpar ▼ (parathyroid hormone)- Dear Healthcare Professional Communication

{healthcare_pro_orange} For Healthcare Professionals
Discontinuation of manufacturing at the end of 2024 and update on 100mcg shortage

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Takeda UK Ltd
Company image
Address
1 Kingdom Street, London, W2 6BD, UK
WWW
www.takeda.com/en-gb/
Telephone
+44 (0)3333 000 181
Medical Information e-mail
[email protected]
Drug Safety e-mail
[email protected]
Medical Information Direct Line
+44 (0)3333 000 181